With Bristol-Myers Squibb’s (NYSE:BMY) acquisition of Celgene (NASDAQ:CELG) expected to close in the third quarter, Celgene’s investors have to make a decision: whether to sell now or take $50 in cash …
More What Should Celgene’s Investors Do With Everything Bristol-Myers Squibb Is Giving Them? Videos